548 results about "Anticancer drug" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention relates to the technical field of bioinformatics and computational biology, and provides an anti-cancer drug target screening method and system based on hypergraph-knowledge graph dual-channel, a hypergraph-knowledge graph dual-channel architecture is constructed through a feature extraction module, a self-adaptive multi-modal fusion module dynamically integrates multi-source heterogeneous data, and the anti-cancer drug target screening method and system based on the hypergraph-knowledge graph dual-channel architecture are obtained. The method comprises the following steps: adaptively fusing high-order interaction features and semantic association features of a gene, generating a high-quality negative sample by using a generative adversarial network to optimize a training process, finally optimizing feature representation through a discriminator, and calculating a synthetic lethal probability score between any gene pair. According to the application, firstly, the extracted multi-dimensional features are normalized through the feature extraction module, then the importance of different features is dynamically weighted based on the attention mechanism, finally, the synthesis lethal relationship prediction probability of the gene pair is output through the multi-layer sensor, and under the theoretical framework of the gene synthesis lethal effect, the synthesis lethal effect of the gene pair is predicted. And an innovative solution is provided for anti-cancer drug target screening.

The invention belongs to the field of bioinformatics, and relates to an anti-cancer drug response prediction method based on an attention mechanism. The method comprises the following steps: firstly, capturing uniform-dimension drug and cancer cell line characteristics through a multi-layer perceptron; secondly, fusing drug characteristics by adopting a Transform encoder, and constructing a cell encoder for cancer cell line characteristic polymerization; then, designing a cross-modal cross fusion module to promote information interaction between the two; and finally, predicting a semi-suppressed concentration value subjected to logarithmic transformation between the two through a multi-layer perceptron. Experimental results show that compared with an existing optimal method, the method has the advantage that the RMSE is reduced by 2.9%. According to the method, accurate prediction of the anti-cancer drug response is achieved by integrating drug and cancer cell line data, screening of potential anti-cancer drugs can be accelerated, personalized treatment schemes can be optimized, the cure rate of cancer patients is further increased, and the method has great significance in cancer treatment.

The invention relates to the field of biological medicine, in particular to IMSFs hydrogel, a ferroptosis induction system, a preparation method and application. The IMSFs hydrogel comprises a hydrogel body, and ferroferric oxide nanoparticles and sorafenib are loaded in the hydrogel body in a wrapping manner. The IMSFs hydrogel can be used as an injectable cascade ferroptosis anti-cancer drug. The preparation method of the IMSFs hydrogel comprises the following steps: firstly, preparing a silk fibroin-hyaluronic acid hydrogel body: dissolving silk hydrogel and hyaluronic acid in a lithium bromide solution; bDDE is added into the dissolved solution, and incubation is carried out; then dialyzing and washing with deionized water to obtain a silk fibroin-hyaluronic acid hydrogel body; and then loading the sorafenib nanoparticles and the ferroferric oxide nanoparticles into the silk fibroin-hyaluronic acid hydrogel body. The IMSFs hydrogel disclosed by the invention integrates magnetic thermal response and drug controlled release, and can be injected to a tumor site, so that the treatment effect on TNBC is remarkably improved.

The invention discloses a drug-combined anticancer composition and application of the composition in preparation of anticancer drugs. According to the present invention, the drug combination composition comprises the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate, the PARP inhibitor Olaparib and the calcium ion antagonist amlodipine maleate provide the synergistic effect, and compared with the single PARP inhibitor, the drug combination composition has characteristics of high stomach cancer sensitivity, significant gastric cancer efficiency improving, and wide application prospect. The Amlodipine in the drug combination composition provided by the invention enhances the curative effect of the PARP inhibitor Olaparib on the gastric cancer.

This invention relates to the field of anticancer drugs, and more particularly to an indole-3-aryl ketone derivative, its preparation method, and its applications. The indole-3-aryl ketone derivative is compound I-VI, which can be used to prepare drugs for the prevention and / or treatment of cancer, including at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer, and esophageal cancer. This invention screened the activity of various compounds and, for the first time, discovered that compound I-VI exhibits excellent inhibitory activity against multiple different types of human cancer cells, providing a potential option for broad-spectrum anticancer drugs.

The present invention relates to a use of THBS1 as a novel combination drug target that can overcome drug resistance of a targeted anticancer agent. A THBS1 inhibitor according to the present invention inhibits the drug resistance of a target anticancer agent and thus increases an anticancer effect when administered in combination with a target anticancer agent. Accordingly, the present invention can overcome resistance to a targeted anticancer agent and increase a treatment success rate of anticancer drugs for cancer patients, thereby suggesting new possibilities for treatment strategies using targeted anticancer drugs and contributing to the realization of precision medicine.

The invention relates to the field of anti-cancer drugs, in particular to an indole-3-aryl ketone derivative as well as a preparation method and application thereof. The indole-3-aryl ketone derivative is a compound I-VI, the indole-3-aryl ketone derivative can be used for preparing drugs for preventing and / or treating cancers, and the cancers comprise at least one of breast cancer, liver cancer, lung cancer, colorectal cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer. According to the invention, activity screening is carried out on various compounds, the fact that the compounds I-VI have excellent inhibitory activity on various different types of human cancer cells is found for the first time, and an optional scheme is provided for broad-spectrum anti-cancer drugs.

Disclosed is an anticancer composition using a flavone derivative. In the present invention, the flavone derivative exhibits cytotoxicity against: H827, H1299, H522, and A549, which are human non-small cell lung cancer cell lines; MCF-7, which is a human breast cancer cell line; and PANC-1, which is a human pancreatic cancer cell line, in a time-dependent manner and in a treatment concentration-dependent manner, and not only exhibits a synergistic effect when used in combination with other conventional anticancer agents, such as osimertinib, which is an anticancer agent targeting for lung cancer, tamoxifen, which is a hormone agent against breast cancer, and gemcitabine, which is a cytotoxic anticancer agent against pancreatic cancer, but also exhibits the effect of synergistically inhibiting the expression of HIF-1α when used alone or in combination with an existing anticancer agent.

The present invention relates to a polypeptide-drug conjugate that binds to IL4Ra and a use thereof, and provides: a polypeptide comprising a ligand that specifically binds to IL4Ra and a temperature-responsive disordered domain; and a polypeptide-drug conjugate in which a cytotoxic drug is bound to the polypeptide. More specifically, the polypeptide, in which an IL4RA-binding ligand and a temperature-responsive disordered domain are repetitively linked, exhibits high selectivity in binding to IL4Ra, and the polypeptide-drug conjugate, in which a cytotoxic drug is bound to the polypeptide, demonstrates significantly enhanced cancer cell-killing efficacy and anti-tumor activity compared to unbound drugs or conventional anticancer agents, and has been confirmed to suppress drug resistance in cancer cells that are resistant to the anticancer agent temozolomide. Accordingly, the polypeptide-drug conjugate can be provided as an effective anticancer therapeutic agent for the treatment of tumors overexpressing IL4Ra and as a pharmaceutical composition for inhibiting drug resistance in cancer cells exhibiting resistance to anticancer drugs.

The invention discloses a synthetic lethal prediction method based on non-generality forgetting and low-rank interaction multi-mode adaptive fusion, and relates to the technical field of bioinformatics, computational biology and drug target screening. The method comprises the following steps: firstly, constructing a multi-view gene embedding expression based on a gene graph structure, a hypergraph structure and a knowledge graph; then constructing a difference vector and an interaction vector for any gene pair so as to characterize the difference and potential complementary relationship between the genes; multi-source information fusion is realized by using a deep learning model containing interactive attention, a forgetting gate and a multi-modal fusion mechanism; on this basis, multi-task optimization is carried out through joint classification loss, modal interaction loss and redundancy suppression loss, and optimal discrimination is realized through a dynamic threshold search strategy; and finally, outputting a sorting result of the candidate synthetic lethal gene pairs according to the prediction score. According to the method, the accuracy and generalization ability of synthetic lethal relationship prediction can be effectively improved, and a high-reliability calculation auxiliary tool is provided for anti-cancer drug target screening and gene therapy strategy design.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

The invention provides an anticancer drug collaborative prediction method MultiFusion Syn based on multi-scale feature fusion, and relates to the technical field of anticancer drug collaborative prediction. According to the method, synergistic effect prediction is converted into a multi-scale feature fusion classification task: a pre-trained graph neural network DGCL is utilized to extract drug fine-grained structure features, ChemBERTa is combined to obtain semantic features, and adaptive fusion is carried out through an attention mechanism; meanwhile, a residual network is adopted to extract biological characteristics of the cell line, drug-cell bidirectional interaction is constructed by means of double-end cross attention, and fine fusion is performed through a gating network; the model introduces a pre-training encoder and realizes knowledge migration in combination with parameter freezing. On a reference data set, MultiFusionSyn is evaluated by indexes such as AUC, PRAUC, ACC and BACC, and the performance of MultiFusionSyn is superior to that of an existing advanced method through verification of an independent test set.

This scheme belongs to the field of organic synthesis technology, discloses the synthesis method of anticancer medicine darolutamide, and the synthesis method designs a new synthesis route: using formula (S1) compound as starting material, first converted into formula (1ab) or formula (1ac) compound, and then converted into formula (TM-1) compound; the obtained formula (TM-1) compound reacts with formula (1ad) or formula (1ae) compound converted from formula (S5) compound to synthesize formula (TM-2) compound, and then converted into formula (TM-3 compound); the obtained formula (TM-3) compound reacts with formula (S6) compound to synthesize formula (TM-4) compound, and then converted into formula (TM-5) darolutamide. The synthesis process does not need to use expensive palladium catalysts or ligands, so there is no problem of heavy metal residues or heavy metal toxicity in the drug product caused by palladium catalysts in the pharmaceutical process, and there is no need to remove trace metal residues from the target product; the raw materials used are cheap and easy to obtain, the reaction system is green and environmentally friendly, simple to handle, high yield, and good purity.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

The present invention constructs a method and system for identifying anticancer peptides based on an attention mechanism and multi-granularity hierarchical features. This method is of great significance in the field of anticancer peptide identification technology. First, atomic-level features are learned through transfer learning, revealing potential features that were difficult to discover in previous work. Secondly, the ChouFasman algorithm is used to represent the secondary structure in the amino acid sequence layer extraction process, which increases the richness of information. Next, the problem that the existing technology cannot capture the high-order structural similarity of anticancer peptide sequences is solved by constructing a hypergraph, and the importance of subsequences to the overall sequence is learned through the attention mechanism. Finally, the multi-granularity hierarchical features are fused, so that the model can fully understand and describe the characteristics of the anticancer peptide sequence. This invention provides a more accurate and comprehensive analysis tool for the discovery and design of anticancer peptides, and can contribute to the development of anticancer drugs.

The invention provides a 1, 3, 4-oxadiazino tetrahydroisoquinoline compound as well as a preparation method and application thereof, and belongs to the technical field of heterocyclic compounds for medicines. The method comprises the following steps: by taking an azomethine imine substrate and a styrene oxide substrate as raw materials and cobalt perchlorate hexahydrate as a catalyst, adding the raw materials and the catalyst into a reaction solvent, reacting overnight at normal temperature, and performing column separation to obtain the 1, 3, 4-oxadiazino tetrahydroisoquinoline compound. According to the application, the reaction condition is mild, the selectivity is high, excellent cytotoxicity is shown on HeLa cervical cancer cells and A549 lung cancer cells, the half death inhibition ratio (IC50) value on tumor cells reaches the nanomole level, and the application has a good anti-cancer drug application prospect.

METHODS OF TREATING CANCER BY ADMINISTERING MCL-1 INHIBITORS AND ANTI-CANCER AGENTS SOLUTION: The present disclosure relates generally to methods for treating cancer by administering an MCL-1 inhibitor and an anti-cancer agent. As is explained in detail in the present specification and as is specifically demonstrated, according to the present invention, a remarkable effect is achieved, which could not be easily expected by those skilled in the art from the prior art.SELECTED DRAWING: Figure 5

The application relates to the frontiers of nanomaterials and drug screening fields, and discloses a fluorescent probe material for drug screening and a drug screening method. The fluorescent probe material realizes screening of anticancer drug efficacy of a to-be-detected drug by detecting the concentration of an NAD+ (nicotinamide adenine dinucleotide) active marker of lactate dehydrogenase, the fluorescent probe material comprises an A agent and a B agent, the A agent is a covalent organic framework material loaded with carbon dots with reducibility, and is denoted as COF@CDs, and the B agent is a transition metal hydride; the transition metal hydride can make NAD+ hydrogenated and reduced into NADH in the presence of the COF@CDs; the product after hydrogen loss of the transition metal hydride can be combined with the COF@CDs, and the COF@CDs can emit fluorescence under excitation light, and the fluorescence is quenched.

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

The present invention relates to a composition for preventing or treating cancer comprising Bifidobacterium longum RAPO (KCTC13773BP), and when used together with immune checkpoint inhibitors (immune anticancer drugs), side effects of immune checkpoint inhibitors are reduced and the effect is more promoted, resulting in an excellent effect in preventing or treating cancer.

The present invention relates to a pharmaceutical composition for preventing or treating tumors, which contains a novel pyrazolopyrimidine compound or a pharma- ceutical acceptable salt thereof as an active ingredient, and which can be usefully used as a composition for preventing or treating cancer by administering it in combination with other anticancer agents.

A composition comprising a naphthoquinone-based compound as an active ingredient and uses thereof are disclosed. The composition is effective for preventing or ameliorating fatigue, cachexia, pain, cognitive decline, and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment. The naphthoquinone-based compounds, dunnione and β-lapachone, reduce the secretion and production of inflammatory cytokines which are increased by the anticancer drug treatment, and prevent fatigue, cachexia, cognitive decline, and hematopoietic stem cell reduction which are side effects associated with anticancer drug treatment.

The invention belongs to the field of anti-cancer drugs, and particularly relates to an anti-cancer porphyrin molecular cage structure and cytotoxic application of the anti-cancer porphyrin molecular cage structure to liver cancer. The invention discloses two coordination molecular cages Pd-TMPP (Cu) and Pd-TMPP (Zn), and detailed and accurate verification is carried out on the structural characteristics and element composition of the two coordination molecular cages through a series of tests. And then the two compounds are modified by hyaluronic acid so as to obtain targeting and water solubility. Experimental results show that the Pd-TMPP (Zn) has concentration-dependent cytotoxicity to HuH-7, Hep-G2 and PLC / PRF / 5, and the cytotoxicity is remarkably enhanced after the Pd-TMPP (Zn) is irradiated by infrared light.

The invention discloses a multi-target carboplatin-platinum (IV) complex as well as a preparation method and application thereof, and belongs to the field of medicinal chemistry. The complex has two different bioactive ligands in the axial direction, carboplatin is used as a raw material, carboplatin is oxidized into oxyplatin in hydrogen peroxide, and then the oxyplatin, axial ligand NHS ester and anhydride are subjected to continuous two-time esterification to obtain a'multi-target 'platinum (IV) anticancer prodrug candidate. 1 / 1 NHS ester and platinum oxide are exchanged in DMSO in the first esterification, and 10 / 1 anhydride and a monosubstituted complex are exchanged in DMF in the second esterification; the reaction raw materials are easy to obtain, the synthesis steps are simple, and the reaction conditions are mild. The multi-target carboplatin complex shows good physiological activity on HeLa, C33A, SiHa and other cervical cancer cells, and is expected to be applied to potential anti-cancer drugs.

The application relates to the technical field of natural medicinal chemistry, and specifically discloses a triterpenoid compound and application, and a preparation method of the compound. The preparation method comprises the following steps: drying and crushing schisandra chinensis roots to obtain dried and crushed schisandra chinensis roots, extracting the dried and crushed schisandra chinensis roots by using 70% ethanol water solution under negative pressure cavitation, combining and concentrating the extract to obtain a crude extract, separating the crude extract by using a D101 macroporous adsorption resin, eluting the crude extract by using water, 30% ethanol, 70% ethanol and 90% ethanol in sequence, collecting a 70% ethanol elution part, performing MCI column chromatography on the 70% ethanol elution part, performing gradient elution on the 70% ethanol elution part by using methanol-water, collecting a depigmentation sample, performing ODS column chromatography on the depigmentation sample, performing gradient elution on the depigmentation sample by using water-methanol, collecting a target component, and purifying the target component by using a preparative high performance liquid chromatograph to obtain the target compound. The application separates a novel triterpenoid compound from schisandra chinensis roots for the first time, expands the development range of medicinal resources of schisandra chinensis plants, simultaneously provides a novel structure mother nucleus and a candidate active molecule for anticancer drug research and development, and enriches the research and development reserves of antitumor natural medicines.

This invention proposes a mechanism-aware synergistic anticancer drug combination prediction method and system, belonging to the field of biomedical technology. It includes: extracting node-level feature representations of the first and second drugs through a drug encoder, and extracting molecular representations of the cell line through a cell line encoder; generating an attention tensor based on a trilinear cross-modal synergistic strategy using a trilinear attention network to explicitly capture the synergistic dependencies of the drug combination in a specific cellular environment, and updating and enhancing the features through context fusion; finally, concatenating the enhanced features and outputting a synergistic score via a multilayer perceptron. This invention can directly model the joint interaction relationship between the first drug, the second drug, and the cell line, thereby accurately predicting the synergistic effect of the anticancer drug combination.

The present invention discloses a polythiocarbamate, its preparation method, and application. The structural formula of the polythiocarbamate of the present invention is: wherein m is a natural number between 110 and 117, and n is a natural number between 6 and 17. The polythiocarbamate of the present invention has excellent biocompatibility and degradability. It can self-assemble in aqueous phase to form nanoparticles and be used as a transport vehicle for fluorescent probes and hydrophobic anticancer drugs. It can specifically amplify H2S signals at tumor sites and can be used for efficient and highly selective tumor imaging and treatment, possessing great potential for clinical application.

This disclosure describes how to treat and / or improve pancreatic cancer using a novel proteomic profile of the pancreatic cancer. In some embodiments, the treatment includes removing cancerous tissue after taking a biopsy from the patient. Optionally, the treatment includes administering anticancer agents to suppress the progression of pancreatic cancer. In further or alternative embodiments, the novel proteomic profile is used to monitor disease progression or remission.

This invention discloses a polysubstituted indole[1,2-a]quinoxaline compound, its preparation method, and its applications. The structural formula of the polysubstituted indole[1,2-a]quinoxaline compound of this invention is or , where R 1 Selected from -H or -F, R 2 The compounds are selected from phenyl, 4-methylphenyl, 4-methoxyphenyl, or 4-fluorophenyl. The polysubstituted indole[1,2-a]quinoxaline compounds of this invention have novel structures and significant antitumor activity, making them suitable for the synthesis of anticancer drugs. Furthermore, their preparation methods offer advantages such as readily available and inexpensive catalysts, broad substrate applicability, good functional group tolerance, simple operation, mild reaction conditions, and high step economy, making them suitable for large-scale industrial production and application.